Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The target population of interest in this study is participants with high-risk HER2-positive early-stage breast cancer. The purpose of this study is to determine the efficacy and safety of T-DXd neoadjuvant therapy.
Participants will be randomised to one of 3 arms: T-DXd monotherapy (Arm A), T-DXd followed by THP (Arm B), or ddAC-THP (Arm C).
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Goiânia, Brazil, 74000-000
- Research Site
-
Ijuí, Brazil, 98700-000
- Research Site
-
Natal, Brazil, 59075-740
- Research Site
-
Porto Alegre, Brazil, 90610-000
- Research Site
-
Porto Alegre, Brazil, 91350-200
- Research Site
-
São Paulo, Brazil, 01221-020
- Research Site
-
São Paulo, Brazil, 01229-010
- Research Site
-
-
-
-
-
Panagyurishte, Bulgaria, 4500
- Research Site
-
Sofia, Bulgaria, 1330
- Research Site
-
-
-
-
-
Montreal, Canada, H3T 1E2
- Research Site
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Research Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X5
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4A-3J1
- Research Site
-
Québec, Quebec, Canada, G1S 4L8
- Research Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Research Site
-
-
-
-
-
Beijing, China, 100039
- Research Site
-
Changsha, China, 410013
- Research Site
-
Changsha, China, 410008
- Research Site
-
Chongqing, China, 400030
- Research Site
-
Guangzhou, China, 510080
- Research Site
-
Guangzhou, China, 510060
- Research Site
-
Guangzhou, China, 510700
- Research Site
-
Kunming, China, 650118
- Research Site
-
Nanning, China, 530021
- Research Site
-
Qingdao, China, 266100
- Research Site
-
Shanghai, China, 200032
- Research Site
-
Shenyang, China, 110001
- Research Site
-
Tianjin, China, 300060
- Research Site
-
Wuhan, China, 430079
- Research Site
-
Wuhan, China, 430060
- Research Site
-
Zhengzhou, China, 450008
- Research Site
-
-
-
-
-
Augsburg, Germany, 86156
- Research Site
-
Berlin, Germany, 10117
- Research Site
-
Erlangen, Germany, 91054
- Research Site
-
Hamburg, Germany, 20357
- Research Site
-
Heidelberg, Germany, 69120
- Research Site
-
Kiel, Germany, 24105
- Research Site
-
Leipzig, Germany, 4103
- Research Site
-
Mönchengladbach, Germany, 41061
- Research Site
-
München, Germany, 81377
- Research Site
-
Münster, Germany, 48149
- Research Site
-
Paderborn, Germany, 33098
- Research Site
-
Tübingen, Germany, 72076
- Research Site
-
-
-
-
-
Gurgaon, India, 122001
- Research Site
-
Howrah, India, 711103
- Research Site
-
Nagpur, India, 440001
- Research Site
-
Nashik, India, 422002
- Research Site
-
New Delhi, India, 110 085
- Research Site
-
New Delhi, India, 110029
- Research Site
-
Raipur, India, 492001
- Research Site
-
Rishikesh, India, 249203
- Research Site
-
Surat, India, 395002
- Research Site
-
Thiruvananthapuram, India, 695011
- Research Site
-
-
-
-
-
Bologna, Italy, 40138
- Research Site
-
Candiolo, Italy, 10060
- Research Site
-
Livorno, Italy, 57100
- Research Site
-
Milan, Italy, 20132
- Research Site
-
Naples, Italy, 80131
- Research Site
-
Negrar, Italy, 37024
- Research Site
-
Padova, Italy, 35128
- Research Site
-
Roma, Italy, 00168
- Research Site
-
Rozzano, Italy, 20089
- Research Site
-
-
-
-
-
Chūōku, Japan, 104-8560
- Research Site
-
Chūōku, Japan, 862-8655
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Research Site
-
Hiroshima, Japan, 734-8551
- Research Site
-
Kawasaki-shi, Japan, 216-8511
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Nagoya, Japan, 466-8560
- Research Site
-
Nagoya, Japan, 467-8602
- Research Site
-
Ota-shi, Japan, 373-8550
- Research Site
-
Shinjuku-ku, Japan, 162-8655
- Research Site
-
-
-
-
-
Lima, Peru, 15033
- Research Site
-
Lima, Peru, LIMA 34
- Research Site
-
Lima, Peru, LIMA 29
- Research Site
-
Lima, Peru, Lima 32
- Research Site
-
-
-
-
-
Bacolod, Philippines, 6100
- Research Site
-
Cebu City, Philippines, 6000
- Research Site
-
Davao City, Philippines, 8000
- Research Site
-
Iloilo City, Philippines, 5000
- Research Site
-
Quezon City, Philippines, 1112
- Research Site
-
San Juan City, Philippines
- Research Site
-
-
-
-
-
Bialystok, Poland, 15-027
- Research Site
-
Biała Podlaska, Poland, 21-500
- Research Site
-
Bydgoszcz, Poland, 85-796
- Research Site
-
Koszalin, Poland, 75-581
- Research Site
-
Lublin, Poland, 20-090
- Research Site
-
Rzeszów, Poland, 30-055
- Research Site
-
Warsaw, Poland, 02-781
- Research Site
-
-
-
-
-
Moscow, Russia, 117997
- Research Site
-
Moscow, Russia, 143423
- Research Site
-
Saint Petersburg, Russia, 197758
- Research Site
-
Saint Petersburg, Russia, 190020
- Research Site
-
-
-
-
-
Dammam, Saudi Arabia, 31444
- Research Site
-
Jeddah, Saudi Arabia, 21423
- Research Site
-
Jeddah, Saudi Arabia, 23214
- Research Site
-
Riyadh, Saudi Arabia, 11426
- Research Site
-
Riyadh, Saudi Arabia, 3354
- Research Site
-
-
-
-
-
Goyang-si, South Korea, 10408
- Research Site
-
Seoul, South Korea, 03080
- Research Site
-
Seoul, South Korea, 03722
- Research Site
-
Seoul, South Korea, 05505
- Research Site
-
Seoul, South Korea, 06273
- Research Site
-
Seoul, South Korea, 06351
- Research Site
-
-
-
-
-
Barcelona, Spain, 08035
- Research Site
-
Barcelona, Spain, 08028
- Research Site
-
Madrid, Spain, 28040
- Research Site
-
Madrid, Spain, 28007
- Research Site
-
Seville, Spain, 41013
- Research Site
-
Vigo, Spain, 36312
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 82445
- Research Site
-
Taichung, Taiwan, 40443
- Research Site
-
Tainan, Taiwan, 710
- Research Site
-
Taipei, Taiwan, 100
- Research Site
-
Taipei, Taiwan, 11217
- Research Site
-
Taipei, Taiwan, 114
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10210
- Research Site
-
Bangkok, Thailand, 10330
- Research Site
-
Bangkok, Thailand, 10400
- Research Site
-
Chiang Mai, Thailand, 50200
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Khon Kaen, Thailand, 40002
- Research Site
-
-
-
-
Arkansas
-
Springdale, Arkansas, United States, 72762
- Research Site
-
-
California
-
Beverly Hills, California, United States, 90211
- Research Site
-
Glendale, California, United States, 91204
- Research Site
-
Los Alamitos, California, United States, 90720
- Research Site
-
Orange, California, United States, 92868
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Research Site
-
Louisville, Kentucky, United States, 40202
- Research Site
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- Research Site
-
-
New Jersey
-
East Brunswick, New Jersey, United States, 08816
- Research Site
-
Summit, New Jersey, United States, 07901
- Research Site
-
-
New York
-
Commack, New York, United States, 11725
- Research Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29607
- Research Site
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Research Site
-
Nashville, Tennessee, United States, 37203
- Research Site
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Research Site
-
-
Utah
-
Ogden, Utah, United States, 84405
- Research Site
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Patients must be at least 18 years of age.
- Histologically documented HER2-positive early breast cancer (EBC) participants, including clinical stage at presentation (based on mammogram or breast MRI assessment): T0-4 (inclusive of inflammatory breast cancer), N1-3, M0 or ≥ T3, N0, M0 as determined by the AJCC staging system, 8th edition
- ECOG performance status of 0 or 1 at randomization
- Adequate organ and bone marrow function
- LVEF ≥ 50% within 28 days before randomization
- FFPE tissue block (2 cores) or 20 freshly-cut, serial tumor slides for HER2 assessment by central lab. If blocks are incomplete or fewer than 20 slides are available, participants may be eligible following discussion with the AstraZeneca Study Physician
Exclusion Criteria:
- prior history of invasive breast cancer
- stage IV breast cancer (determined by AJCC staging system)
- any primary malignancy within 3 years (except resected non-melanoma skin cancer, curatively treated in situ disease) Note: This includes a second current breast primary malignancy (ie, bilateral breast cancer)
- history of DCIS (except those treated with mastectomy >5 years prior to current diagnosis)
- History of, or current, ILD/pneumonitis
- Prior systemic therapy for the treatment of breast cancer
- Previous treatment with anthracyclines, cyclophosphamide or taxanes for any malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A
Trastuzumab deruxtecan
|
administered by intravenous infusion
Other Names:
|
|
Experimental: Arm B
T-DXd, followed by THP
|
administered by intravenous infusion
Other Names:
administered by intravenous infusion
Other Names:
administered by intravenous infusion
Other Names:
administered by intravenous infusion
Other Names:
|
|
Active Comparator: Arm C
doxorubicin and cyclophosphamide, followed by THP
|
administered by intravenous infusion
Other Names:
administered by intravenous infusion
Other Names:
administered by intravenous infusion
Other Names:
administered by intravenous infusion
Other Names:
administered by intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Pathologic Complete Response (pCR).
Time Frame: Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)
|
Proportion of participants who have no evidence by Hematoxylin & Eosin (H&E) staining of residual invasive disease in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by central evaluation following completion of neoadjuvant therapy.
|
Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Event-Free Survival (Count)
Time Frame: Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)
|
Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.
|
Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)
|
|
Event-Free Survival (Duration)
Time Frame: Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)
|
Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.
|
Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Skin Diseases
- Breast Diseases
- Skin and Connective Tissue Diseases
- Breast Neoplasms
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Carbohydrates
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glycosides
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Taxoids
- Cyclodecanes
- Diterpenes
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Anthracyclines
- Naphthacenes
- Aminoglycosides
- Daunorubicin
- Trastuzumab
- Cyclophosphamide
- Doxorubicin
- Paclitaxel
- pertuzumab
- trastuzumab deruxtecan
Other Study ID Numbers
Other Study ID Numbers
- D967RC00001
- 2021-000603-21 (EudraCT Number)
- 2023-505210-18-00 (Registry Identifier: CTIS (EU))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.